University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Epidemiology

Epidemiology

2022

Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A
Case Series From a 12-Month Longitudinal Occupational Cohort
Christina D. Mack
Caroline Tai
Robby Sikka
Yonatan H. Grad
Lisa L. Maragakis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unmc.edu/coph_epidem_articles
Part of the Epidemiology Commons

Authors
Christina D. Mack, Caroline Tai, Robby Sikka, Yonatan H. Grad, Lisa L. Maragakis, Nathan D. Grubaugh,
Deverick J. Anderson, David Ho, Michael Merson, Radhika M. Samant, Joseph R. Fauver, James Barrett,
Leroy Sims, and John DiFiori

Clinical Infectious Diseases
BRIEF REPORT

Christina D. Mack,1 Caroline Tai,1 Robby Sikka,2 Yonatan H. Grad,3
Lisa L. Maragakis,4 Nathan D. Grubaugh,5 Deverick J. Anderson,6,7 David Ho,8
Michael Merson,9 Radhika M. Samant,1 Joseph R. Fauver,5 James Barrett,10
Leroy Sims,11 and John DiFiori11,12
1

Real World Solutions, IQVIA, Durham, North Carolina, USA; 2Minnesota Timberwolves,
Minneapolis, Minnesota, USA; 3Harvard T.H. Chan School of Public Health, Boston, Massachusetts,
USA; 4Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 5Yale School
of Public Health, Yale University, New Haven, Connecticut, USA; 6Duke Center for Antimicrobial
Stewardship and Infection Prevention, Duke University School of Medicine, Durham, North
Carolina, USA; 7Infection Control Education for Major Sports, Chapel Hill, North Carolina, USA;
8
Aaron Diamond AIDS Research Center, Columbia University Department of Microbiology and
Immunology, New York, New York, USA; 9Global Health Institute, Duke University, Durham, North
Carolina, USA; 10Family and Preventive Medicine, University of Oklahoma College of Medicine,
Oklahoma City, Oklahoma, USA; 11National Basketball Association, New York, New York, USA; and
12
Primary Sports Medicine, Hospital for Special Surgery, New York, New York, USA

Findings are described in 7 patients with severe acute respiratory syndrome coronavirus 2 reinfection from the National
Basketball Association 2020–2021 occupational testing cohort, including clinical details, antibody test results, genomic
sequencing, and longitudinal reverse-transcription polymerase
chain reaction results. Reinfections were infrequent and varied
in clinical presentation, viral dynamics, and immune response.
Keywords. SARS-CoV-2; COVID-19; reinfection; asymptomatic; surveillance.

Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection was diagnosed in >30 million individuals in
the United States between 1 March 2020 and 30 May 2021 [1].
The strength and duration of immunity after infection, vaccination, and in response to SARS-CoV-2 variants remain key unknowns that will shape the future of coronavirus disease 2019
(COVID-19) spread. To date, the majority of reported SARSCoV-2 reinfection cases have limited clinical details [2, 3].
A deeper understanding of the patterns and factors influencing
COVID-19 reinfection is important to inform clinical and
public health policy decisions. This report presents 7 cases of
COVID-19 reinfection observed from the National Basketball
Association (NBA) occupational COVID-19 testing program,
with relevant clinical details.
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METHODS

The NBA occupational COVID-19 testing program provides an
opportunity to detect and diagnose SARS-CoV-2 infections and
reinfections, even among asymptomatic individuals [4]. NBA
players, staff and vendors who participated in the US-based
2020–2021 NBA season as well as associated household members were tested for SARS-CoV-2 using frequent serial reversetranscription polymerase chain reaction (RT-PCR) testing of
combined anterior nasal and oropharyngeal swab samples and
other testing platforms as part of occupational health and safety
protocols during the COVID-19 pandemic. Testing frequency
depended on an individual’s role, but for many the testing cadence was daily. This longitudinal data set includes RT-PCR
results, demographics, clinical information, infection history,
antibody titer levels, SARS-CoV-2 variant information, and
the presence and nature of symptoms for individuals who experienced a reinfection between 1 December 2020 and 30 May
2021. This retrospective observational study was approved by
the Advarra Institutional Review Board.

RESULTS

Of 7980 individuals monitored during the 6-month study period, 768 team staff, arena staff, third-party vendors, players,
or household members of any of these groups reported or were
found to have recovered from a prior infection, defined as a
confirmed positive RT-PCR test result plus symptoms, sequential positive RT-PCR results, and/or presence of antibodies (in
unvaccinated individuals) at any point since the emergence of
the COVID-19 pandemic; 7 of these experienced reinfections
after a documented first infection. The reliable documentation
of first infection coupled with serial testing, during and after
reinfection, maximized the likelihood of detecting reinfections.
We observed variation in symptoms, viral dynamics as measured by RT-PCR cycle threshold (Ct) values (open reading
frame [ORF] 1 a/b nonstructural region), and the levels of anti–
SARS-CoV-2 antibodies among the 7 people with diagnosed
reinfection (Table 1). All patients with reinfection were male,
and their ages at reinfection ranged from 19 to 44 years (mean,
30 years). Six of the 7 individuals (86%) were asymptomatic at
the time of reinfection; patient 7, who was immunocompromised, experienced headaches, myalgia, and an altered sense of
taste and smell at the time of reinfection. In addition, patient
4 experienced gastrointestinal symptoms 9 days from the first
positive test linked to his reinfection. Six of 7 patients (86%) had
detectable SARS-CoV-2 antibodies at or soon before the time
of reinfection, with a mean level of 23.0 arbitrary units (AU)/
mL (range, 6.7–37.9 AU/mL), noting that the time interval from
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Antibody titer obtained ≥7 days after the onset of reinfection.
Two consecutive negative test results after reinfection is the key clinical criterion defining recovery from/clearance of reinfection.
e

d

Target 1 for the Roche Cobas diagnostic platform, open reading frame (ORF) 1, which is specific to the detection of SARS-CoV-2.

Variants listed use Phylogenetic Assignment of Named Global Outbreak Lineages [Pangolin] nomenclature.
c

b

All listed titer values correspond to the DiaSorin LIAISON platform. Dates of initial infection were self-reported by individuals; while most were confirmed by documentation of a positive test result with a date of collection, initial infection dates were approximated by patients 5 and 6, owing to lack of documentation for the collection date.

Antibody tests were conducted using one of the following platforms, which differed in the target antigen of SARS-CoV-2: the DiaSorin LIAISON system, which detects immunoglobulin (Ig) G antibodies to the S1/S2 antigens; the Roche Elecsys system,
which detects IgG antibodies to the nucleocapsid antigen; the Abbott Architect system, which detects IgG antibodies to the nucleocapsid antigen; and the Ortho VITROS system, which detects IgG antibodies to the S1 antigen.

a
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Abbreviations: AU, arbitrary units; Ct, cycle threshold; d, days; NA, not available; ND, not detected; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

6

4
NA

NA
NA

NA

NA

NA

No

No

35.24

33.57

66

106
25.9

37.9
No

No

156

182

5

6

11

14
NA

23
155.0

NA
NA

B.1.1.7
No

Yes

28.98

32.56

80

79
6.7

23.1

101

No
198
3

4

No

11

5
63

8
20.8

22.0
NA

B.1.2

No

No

28.47

25.36

1

40
9.0

35.2
No

196

No

204

2

Patient

1

Time From
Reinfection to
Clearance, de
Time From
Reinfection to
Antibody Titer, d
Antibody Titer After
Reinfection,
AU/mLa,d
SARS-CoV-2
Variant at
Reinfectionc
Symptomatic
During
Reinfection
Nadir Ct During
Reinfectionb
Time From
Antibody Titer to
Reinfection, d
Antibody Titer
Before Reinfection,
AU/mLa
Symptomatic
During Initial
Infection
Time From Initial
Positive Test to
Reinfection, d

Clinical Characteristics of Reinfection
Table 1.

DISCUSSION

The viral trajectories of the reinfections differed from the patterns observed in this population among those with primary
infections, with mean nadir Ct (representing peak viral load) of
28.70 (range, 16.75–35.24) during reinfection, compared with
the previously reported mean nadir of 22.4 Ct (95% credible
interval, 20.2–24.5) (Supplementary Figure 1) [6]. While the
intervals overlap, the difference in means suggests lower viral
loads during reinfection compared with primary infection.
This difference could indicate reduced viral replication during
infection for individuals who already have antibodies to SARSCoV-2, compared with COVID-19–naive individuals. Although
this is a limited sample size, findings in the patients presented
here suggest that immune responses and viral control may vary
among individuals, whether owing to pharmacokinetics, undiagnosed immunodeficiencies, and/or other factors. The mean
time between primary infection and reinfection was 152 days
(median, 182 days; range, 25–204 days, including the immunocompromised patient), consistent with findings of a previous
study on reinfection [2].
Among the 7 detected reinfections, 6 (86%) were subclinical at the time of the first positive test, and likely undetectable
BRIEF REPORT • CID 2022:74 (1 May) • 1683
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the most recent antibody measurement to reinfection varied
(range, 0–106 days). In 2 of the 7 patients (29%; patients 2 and
3), anti–SARS-CoV-2 antibody levels increased after reinfection by 11.8 and 131.9 AU/mL. Patient 7 did not have detectable
antibodies on the day of reinfection but exhibited seroconversion by day 33 after reinfection, with an antibody titer of 22.5
AU/mL. The remaining patients (patients 4, 5, and 6) did not
undergo antibody testing after recovery from their reinfection
(Supplementary Table 1).
The timing of the antibody tests varied, because these were
optional tests performed for clinical or diagnostic reasons (eg,
real-world use) rather than as part of a research protocol. The
presence of antibodies at time of reinfection in these patients
highlights the question of how much certain quantitative results
from commercially available antibody tests indicate protection
from SARS-CoV-2 infection. Spike protein–directed antibody
levels correlate well with virus-neutralizing titers [5], but the
precise level of neutralizing antibodies necessary for protection
from reinfection, and the translation of such levels to commercially available antibody tests, remains unclear. SARS-CoV-2
genomic sequencing was not performed on isolates from the
primary infections. Among the 3 reinfected individuals whose
samples were sequenced, 2 variants were detected: B.1.1.7 (patient 3) and B.1.2 (patients 2 and 7). Genomic sequencing results support a common transmission pathway between these
patients and their exposure contacts, sharing the same variants
and similar genomes. The viral genome for the close contact of
patient 7 could not be sent for sequencing.
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Clinically relevant COVID-19 reinfections, both symptomatic and asymptomatic, do occur, although infrequently in
this longitudinal cohort. The diversity of patterns observed
here presents interesting immunological questions, relevant
to current vaccine and preparedness plans. As SARS-CoV-2
variants emerge, cases of COVID-19 reinfection present
an opportunity to understand real-world effectiveness of
vaccines and postinfection immunity beyond clinical trial
settings. Such insights are critical to inform infection prevention efforts. These case studies and discussion are intended to stimulate others to consider this information, to
build knowledge of reinfection, and to inform clinical management and policy.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online.
Consisting of data provided by the authors to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the authors, so
questions or comments should be addressed to the corresponding author.
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without the serial testing program. Despite the lack of clinical
symptoms, 4 of these individuals had nadir Ct values ranging
from 16.75 to 28.98 during reinfection, which may have been
sufficient for viral transmission to others [8]. To date, there is
limited evidence on the transmission risk for recovered individuals who are reinfected [9], although there have been reports of
Ct values <30 in cases of reinfection [10, 11].
The patients discussed here fit the clinical pattern of reinfection based on longitudinal RT-PCR surveillance results,
symptoms, and serology (Supplementary Figure 2) although
lack of longitudinal genomic sequencing cannot rule out viral
persistence. All patients, except patient 1, were known to have
unmasked exposure to an individual who tested positive for
SARS-CoV-2 within 1 week before their reinfection (each of
the presented cases were distinct and unrelated). Although it
is possible that these are not all true reinfections, the quality
and reliability of the epidemiological and longitudinal data offer
strong evidence of reinfection and provide a complete clinical
illustration of these cases.
Patient 7, the only patient who lacked detectable SARS-CoV-2
antibodies at the time of reinfection, was reinfected within
30 days of the initial RT-PCR–confirmed primary infection. The
rapid reinfection led to an evaluation for immunocompromising
conditions and subsequent diagnosis of a mild immunodeficiency disorder, which likely explains the lack of antibodies
after initial infection. This individual had distinct COVID-19
symptoms during the primary infection (moderate respiratory
symptoms) compared with the reinfection (headaches, myalgia, anosmia, and dysgeusia) and had completely recovered
from his initial symptoms before reinfection, supportive of the
COVID-19 diagnosis as well as clinically suggesting 2 separate
infections.
It is possible that these cases could represent false-positive
results, transient virus, or a continuation/reactivation of the
primary infection rather than reinfection; to some extent, diagnostic uncertainty is clinically instructive, as we work to better
understand reinfection.
The population assessed in this study was predominantly
male, unvaccinated, relatively young, and healthy compared
with the general population. As noted by Váncsa et al, younger
patients may display a longer period of viral shedding, but also
may present with a second infection later than older patients
[11]. In this population, we did not observe intermittent positive RT-PCR results between the initial and the second infection, despite frequent testing, except in patient 6, who tested
positive with a high Ct value (the same sample was reprocessed
and was negative on a less sensitive machine), 10 days before
reinfection, and negative 3 times before reinfection. Ct values
were not available for initial infection, and owing to the small
number of individuals here, the effect of emerging variants and
the impact of vaccination on reinfection rates could not be
assessed.
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Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod
tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id
est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed
do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
ut aliquip ex ea commodo consequat. Duis aute irure dolor in
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet,
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit
amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem
ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
non proident, sunt in culpa qui officia deserunt mollit anim id est
laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do
academic.oup.com/cid
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eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
ea commodo consequat. Duis aute irure dolor in reprehenderit in
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
ut aliquip ex ea commodo consequat. Duis aute irure dolor in
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet,
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit
amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem
ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
non proident, sunt in culpa qui officia deserunt mollit anim id est
laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do
eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
ea commodo consequat. Duis aute irure dolor in reprehenderit in
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
academic.oup.com/cid
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Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
ut aliquip ex ea commodo consequat. Duis aute irure dolor in
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet,
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit
amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem
ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
non proident, sunt in culpa qui officia deserunt mollit anim id est
laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do
eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
ea commodo consequat. Duis aute irure dolor in reprehenderit in
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
ut aliquip ex ea commodo consequat. Duis aute irure dolor in
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
deserunt mollit anim id est laborum.
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